Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)
Open Access
- 30 January 2018
- journal article
- research article
- Published by Springer Nature in BMC Ophthalmology
- Vol. 18 (1) , 19
Abstract
Retinopathy of Prematurity (ROP) is one of the most common causes of childhood blindness worldwide. Comparisons of anti-VEGF and laser treatments in ROP are relatively lacking, and the data are scattered and limited. The objective of this meta-analysis is to compare the efficacy of both treatments in type-1 and threshold ROP. A comprehensive literature search on ROP treatment was conducted using PubMed and Embase up to March 2017 in all languages. Major evaluation indexes were extracted from the included studies by two authors. The fixed-effects and random-effects models were used to measure the pooled estimates. The test of heterogeneity was performed using the Q statistic. Ten studies were included in this meta-analysis. Retreatment incidence was significantly increased for anti-VEGF (OR 2.52; 95% CI 1.37 to 4.66; P = 0.003) compared to the laser treatment, while the incidences of eye complications (OR 0.29; 95% CI 0.10 to 0.82; P = 0.02) and myopia were significantly decreased with anti-VEGF compared to the laser treatment. However, there was no difference in the recurrence incidence (OR 1.86; 95% CI 0.37 to 9.40; P = 0.45) and time between treatment and retreatment (WMD 7.54 weeks; 95% CI 2.00 to 17.08; P = 0.12). This meta-analysis indicates that laser treatment may be more efficacious than anti-VEGF treatment. However, the results of this meta-analysis also suggest that laser treatment may cause more eye complications and increase myopia. Large-scale prospective RCTs should be performed to assess the efficacy and safety of anti-VEGF versus laser treatment in the future.Keywords
This publication has 49 references indexed in Scilit:
- Intravitreal Bevacizumab for Retinopathy of Prematurity: Refractive Error ResultsAmerican Journal of Ophthalmology, 2013
- LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-upRetina, 2013
- Prentice Award Lecture 2010: A Case for Peripheral Optical Treatment Strategies for MyopiaOptometry and Vision Science, 2011
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in TaiwanOphthalmology, 2011
- Redundant Mechanisms for Vascular Growth Factors in Retinopathy of Prematurity in vitroOphthalmic Research, 2010
- Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurityActa Ophthalmologica, 2008
- DIODE LASER TREATMENT OF RETINOPATHY OF PREMATURITYRetina, 2008
- LASER TREATMENT FOR RETINOPATHY OF PREMATURITYRetina, 2006
- A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 yearsOphthalmology, 2002